Curis Inc
NASDAQ:CRIS

Watchlist Manager
Curis Inc Logo
Curis Inc
NASDAQ:CRIS
Watchlist
Price: 0.9183 USD 2.1% Market Closed
Market Cap: $11.9m

Operating Margin

-294.6%
Current
Improving
by 143.4%
vs 3-y average of -438.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-294.6%
=
Operating Income
$-34.3m
/
Revenue
$11.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-294.6%
=
Operating Income
$-34.3m
/
Revenue
$11.7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Curis Inc
NASDAQ:CRIS
11.5m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 14 112 companies
10th percentile
-294.6%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Curis Inc
Glance View

Market Cap
11.9m USD
Industry
Biotechnology

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.

CRIS Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-294.6%
=
Operating Income
$-34.3m
/
Revenue
$11.7m
What is Curis Inc's current Operating Margin?

The current Operating Margin for Curis Inc is -294.6%, which is above its 3-year median of -438.1%.

How has Operating Margin changed over time?

Over the last 3 years, Curis Inc’s Operating Margin has increased from -531.4% to -294.6%. During this period, it reached a low of -531.4% on Sep 30, 2022 and a high of -294.6% on Sep 30, 2025.

Back to Top